Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.93 USD | -9.65% | -5.97% | -19.94% |
04:29pm | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
04/06 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.94% | 524M | |
+52.57% | 55.7B | |
+40.57% | 39.91B | |
-6.50% | 39.57B | |
-6.65% | 28.16B | |
+14.98% | 26.3B | |
-20.39% | 18.94B | |
+31.18% | 12.17B | |
+27.02% | 12.12B | |
+0.49% | 12.12B |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Transcript : COMPASS Pathways plc, Q3 2023 Earnings Call, Nov 02, 2023